The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients?
Lung cancer is the leading cause of cancer-related death. Over the past 5–10 years lung cancer outcomes have significantly improved in part due to better treatment options including immunotherapy and molecularly targeted agents. Unfortunately, the majority of lung cancer patients do not enjoy durabl...
Main Authors: | Frank Weinberg, Robert P. Dickson, Deepak Nagrath, Nithya Ramnath |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/1/13 |
Similar Items
-
Comprehensive sampling of the lung microbiome in early-stage non–small cell lung cancerCentral MessagePerspective
by: Rishindra M. Reddy, MD, MBA, et al.
Published: (2024-02-01) -
Gut Microbiome Was Highly Related to the Regulation of Metabolism in Lung Adenocarcinoma Patients
by: Sheng Wang, et al.
Published: (2022-05-01) -
Association Studies on Gut and Lung Microbiomes in Patients with Lung Adenocarcinoma
by: Yaqiong Guo, et al.
Published: (2023-02-01) -
Oral application of vancomycin alters murine lung microbiome and pulmonary immune responses
by: Stefan Pfeiffer, et al.
Published: (2022-08-01) -
Lung cancer progression alters lung and gut microbiomes and lipid metabolism
by: Mao Hagihara, et al.
Published: (2024-01-01)